Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company. It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company's clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic. Its clinical studies for compounds have commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary aldosteronism, a cause of hypertension. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.